{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:12:22Z","timestamp":1791623542987,"version":"4.3.4"},"reference-count":56,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Pegfilgrastim-apgf (nyvepria) was currently approved by FDA for the treatment of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive anticancer drugs. It was developed by Pfizer, USA. It is a PEGylated leukocyte growth-stimulating factor indicated to reduce the incidence of febrile neutropenia in patients receiving anticancer drugs. Nyvepria is biosim-ilar to pegfilgrastim, approved by FDA on June 10, 2020. It is the fourth FDA-approved drug for the treatment of infection exhibiting febrile neutropenia. This review abridges the indicators in the devel-opment of nyvepria foremost to approval for the treatment of febrile neutropenia (FN), a biosimilar regulatory framework, and current updates on the clinical trials (CTs).<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450123666220408101152","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T05:18:50Z","timestamp":1649654330000},"page":"924-932","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the\nTreatment of Chemotherapy-induced Febrile Neutropenia and Current\nUpdates on Clinical Trials"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-4223","authenticated-orcid":true,"given":"Faraat","family":"Ali","sequence":"first","affiliation":[{"name":"Laboratory Services, Botswana Medicines Regulatory Authority, Plot 112, International Finance Park, Gaborone,\nBotswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamna","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, Indo-Soviet Friendship College of Pharmacy, Moga, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard University, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1016\/S1470-2045(16)30374-6","volume":"17","author":"Schellekens H.","year":"2016","unstructured":"Schellekens H.; Smolen J.S.; Dicato M.; Rifkin R.M.; Safety and efficacy of biosimilars in oncology. Lancet Oncol 2016,17(11),e502-e509","journal-title":"Lancet Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","volume":"120","author":"Weise M.","year":"2012","unstructured":"Weise M.; Bielsky M.C.; De Smet K.; Biosimilars: What clinicians should know. Blood 2012,120(26),5111-5117","journal-title":"Blood"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000105133","volume":"30","author":"Nowicki M.","year":"2007","unstructured":"Nowicki M.; Basic facts about biosimilars. Kidney Blood Press Res 2007,30(5),267-272","journal-title":"Kidney Blood Press Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.2017.77.4893","volume":"36","author":"Lyman G.H.","year":"2018","unstructured":"Lyman G.H.; Balaban E.; Diaz M.; American society of clinical oncology statement: Biosimilars in oncology. J Clin Oncol 2018,36(12),1260-1265","journal-title":"J Clin Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/ph5121393","volume":"5","author":"Calo-Fern\u00e1ndez B.","year":"2012","unstructured":"Calo-Fern\u00e1ndez B.; Mart\u00ednez-Hurtado J.L.; Biosimilars: Company strategies to capture value from the biologics market. Pharmaceuticals (Basel) 2012,5(12),1393-1408","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40259-013-0020-y","volume":"27","author":"Tsiftsoglou A.S.","year":"2013","unstructured":"Tsiftsoglou A.S.; Ruiz S.; Schneider C.K.; Development and regulation of biosimilars: Current status and future challenges. BioDrugs 2013,27(3),203-211","journal-title":"BioDrugs"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.17925\/OHR.2016.12.01.22","volume":"12","author":"Zelenetz A.D.","year":"2016","unstructured":"Zelenetz A.D.; Biosimilars in oncology. Oncol Hematol Rev 2016,12(1),22-28","journal-title":"Oncol Hematol Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jamaoncol.2017.2004","volume":"4","author":"Nabhan C.","year":"2018","unstructured":"Nabhan C.; Parsad S.; Mato A.R.; Feinberg B.A.; Biosimilars in oncology in the united states: A review. JAMA Oncol 2018,4(2),241-247","journal-title":"JAMA Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-017-0743-z","volume":"77","author":"Camacho L.H.","year":"2017","unstructured":"Camacho L.H.; Current status of biosimilars in oncology. Drugs 2017,77(9),985-997","journal-title":"Drugs"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1517\/14712591003796553","volume":"10","author":"Roger S.D.","year":"2010","unstructured":"Roger S.D.; Biosimilars: Current status and future directions. Expert Opin Biol Ther 2010,10(7),1011-1018","journal-title":"Expert Opin Biol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejpb.2009.02.014","volume":"72","author":"Kresse G.B.","year":"2009","unstructured":"Kresse G.B.; Biosimilars--science, status, and strategic perspective. Eur J Pharm Biopharm 2009,72(3),479-486","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2165\/11593730-000000000-00000","volume":"71","author":"Dranitsaris G.","year":"2011","unstructured":"Dranitsaris G.; Amir E.; Dorward K.; Biosimilars of biological drug therapies: Regulatory, clinical and commercial considerations. Drugs 2011,71(12),1527-1536","journal-title":"Drugs"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.03.008","volume":"41","author":"Rak Tkaczuk K.H.","year":"2014","unstructured":"Rak Tkaczuk K.H.; Jacobs I.A.; Biosimilars in oncology: From development to clinical practice. Semin Oncol 2014,41(2)(Suppl. 3),S3-S12","journal-title":"Semin Oncol"},{"key":"ref=14","unstructured":"Filgrastim. Drugbank online | database for drug and drug target info. Available from:"},{"key":"ref=15","unstructured":"Lenograstim. Drugbank online | database for drug and drug target info. Available from:"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1080\/10428190902756081","volume":"50","author":"Engert A.","year":"2009","unstructured":"Engert A.; Griskevicius L.; Zyuzgin Y.; Lubenau H.; del Giglio A.; XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009,50(3),374-379","journal-title":"Leuk Lymphoma"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","volume":"24","author":"Gasc\u00f3n P.","year":"2016","unstructured":"Gasc\u00f3n P.; Aapro M.; Ludwig H.; Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutro-penia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer 2016,24(2),911-925","journal-title":"Support Care Cancer"},{"key":"ref=18","year":"2020","unstructured":"Nyvepria (pegfilgrastim-apgf) FDA Approval History. Available from: 2020"},{"key":"ref=19","year":"2020","unstructured":"First BiosimilarPegfilgrastim Gets FDA ApprovalAvailable from: 2020"},{"key":"ref=20","unstructured":"Biosimilar Development, Review, and Approval. Available from:"},{"key":"ref=21","unstructured":"Pegfilgrastim. Drugs.com Drugs.com | Prescription Drug Information, Interactions"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"i2721","DOI":"10.1136\/bmj.i2721","volume":"353","author":"Aronson J.K.","year":"2016","unstructured":"Aronson J.K.; Ferner R.E.; How similar are biosimilars? BMJ 2016,353,i2721","journal-title":"BMJ"},{"key":"ref=23","year":"2002","unstructured":"Neulasta. Prescribing information. Amgen Inc. Available from:  (Accessed June 3, 2021).2002"},{"key":"ref=24","year":"2018","unstructured":"US FDA approves UDENYCA (pegfilgrastim-cbqv). News release. CoherusBioSciences, Inc. November 2. Coherus Biosciences, Inc.Available from:  (Accessed June 3)2018"},{"key":"ref=25","year":"2021","unstructured":"Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo (pegfilgrastim-bmez). Available from:  (Accessed 2021 June 3).2021"},{"key":"ref=26","year":"2021","unstructured":"FDA approves Pfizer\u2019s oncology supportive care biosimilar, Nyvepria (pegfilgrastim-apgf). Available from:  (Accessed 2021, June 3).2021"},{"key":"ref=27","year":"2020","unstructured":"FDA approves Pfizer\u2019s oncology supportive care biosimilar Nyvepria\u2122 (Pegfilgrastim-apgf). Available from: 2020"},{"key":"ref=28","year":"2020","unstructured":"Uses, Dosage, Side Effects, Interactions, Warning Nyvepria (Pegfilgrastim-apgf Injection)Available from 2020","journal-title":"Uses, Dosage, Side Effects, Interactions, Warning"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.drudis.2015.03.011","volume":"20","author":"Bui L.A.","year":"2015","unstructured":"Bui L.A.; Hurst S.; Finch G.L.; Key considerations in the preclinical development of biosimilars. Drug Discov Today 2015,20(Suppl. 1),3-15","journal-title":"Drug Discov Today"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1570163818666210519103001","volume":"19","author":"Ali F","year":"2022","unstructured":"Ali F; Sharma K; Anjum V; Ali A.; Inebilizumab-cdon: USFDA approval for the treatment of NMOSD (neuromyelitis optica spectrum disorder). Curr Drug Discov Technol 2021 2022,19(1),22-28","journal-title":"Curr Drug Discov Technol 2021"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1201\/9781003106524-32","author":"Ali F.","year":"2022","unstructured":"Ali F.; Ahmad J.;  Regulatory status of bioactive peptides bioactive peptides from food 2022","journal-title":"Regulatory status of bioactive peptides bioactive peptides from food"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00280-017-3510-7","volume":"81","author":"Esteva F.J.","year":"2018","unstructured":"Esteva F.J.; Stebbing J.; Wood-Horrall R.N.; Winkle P.J.; Lee S.Y.; Lee S.J.; A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother Pharmacol 2018,81(3),505-514","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=33","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106143","volume":"165","author":"Ratih R.","year":"2021","unstructured":"Ratih R.; Asmari M.; Megied M.A.; Ahmed, Elbarbry F, Deeb SE. Biosimilars: Review of regulatory, manufacturing, analytical aspects and beyond. Microchem J 2021,165","journal-title":"Microchem J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ajps.2015.08.011","volume":"11","author":"Mishra P.","year":"2016","unstructured":"Mishra P.; Nayak B.; Dey R.K.; PEGylation in anti-cancer therapy: An overview. Asian J Pharm Sci 2016,11(11),337-348","journal-title":"Asian J Pharm Sci"},{"key":"ref=35","first-page":"175","author":"Patel Krish","year":"2017","unstructured":"Patel Krish; Howard M.D.; Febrile neutropenia. JAMA Oncol 2017(12),175","journal-title":"JAMA Oncol"},{"key":"ref=36","year":"2020","unstructured":"FDA approves nyvepria, a biosimilar to neulasta for febrile neutropenia. Available from: 2020"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00520-017-3842-1","volume":"25","author":"Aapro M.","year":"2017","unstructured":"Aapro M.; Boccia R.; Leonard R.; Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer 2017,25(11),3295-3304","journal-title":"Support Care Cancer"},{"key":"ref=38","year":"2020","unstructured":"NYVEPRIA\u2122 (Pegfilgrastim-apgf) injection, for subcutaneous use Initial U.S. Available from: 2020"},{"key":"ref=39","volume":"23","author":"Krendyukov A.","year":"2019","unstructured":"Krendyukov A.; Schiestl M.; Biosimilars in oncology: A decade of experience with granulocyte colony stimulating factor and its implications for monoclonal antibodies. Crit Rev Oncol 2019,23","journal-title":"Crit Rev Oncol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(17)30434-5","volume":"18","author":"Stebbing J.","year":"2017","unstructured":"Stebbing J.; Baranau Y.; Baryash V.; CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: A randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017,18(7),917-928","journal-title":"Lancet Oncol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1188\/03.CJON.238-241","volume":"7","author":"Phillips M.S.","year":"2003","unstructured":"Phillips M.S.; Pegfilgrastim. Clin J Oncol Nurs 2003,7(2),238-239","journal-title":"Clin J Oncol Nurs"},{"key":"ref=42","year":"2020","unstructured":"FDA Approves Nyvepria (Pegfilgrastim-apgf), a Biosimilar to Neulasta. Available from:  2020"},{"key":"ref=43","year":"2020","unstructured":"Nyvepria\u2122 (Pegfilgrastim-apgf) new biosimilar approval. Available from: 2020"},{"key":"ref=44","year":"2020","unstructured":"FDA Approves Peglgrastim-apgf, Biosimilar to Peglgrastim. Cancer Network. Available from: 2020"},{"key":"ref=45","year":"2020","unstructured":"Immunogenicity assessment of peg-filgrastim vs. Neulasta\u00ae as Adjunct to chemotherapy in patients with breast cancer 2020. 2020"},{"key":"ref=46","year":"2020","unstructured":"Impact of pegfilgrastim on trastuzumab anti-tumor effect and ADCC in operable HER2+ breast cancer breast cancer 2020. 2020"},{"key":"ref=47","year":"2020","unstructured":"Feasibility and cost analysis of pbsc mobilization using pegfilgrastim in hematologic malignancies. 2020"},{"key":"ref=48","year":"2020","unstructured":"Pharmacokinetics and pharmacodynamics comparison study between two pegfilgrastim formulations. 2020"},{"key":"ref=49","year":"2020","unstructured":"A comparative study on efficacy and safety of lipegfilgrastim in comparison to pegfilgrastim in elderly patients with aggressive B cell non-hodgkin lymphomas at high risk for R-CHOP-21-induced neutropenia. 2020"},{"key":"ref=50","year":"2020","unstructured":"Patient preference for pegfilgrastim (Neulasta\u00ae) application forms 2020. 2020"},{"key":"ref=51","unstructured":"Pegfilgrastim on day +3 compared to day +1 after salvage chemotherapy for patients with refractory or relapsed aggressive lymphoma."},{"key":"ref=52","year":"2020","unstructured":"Assessing the immunogenicity of 2 subcutaneous doses of CHS-1701 (CoherusPegfilgrastim) with 2 subcutaneous doses neulasta. 2020"},{"key":"ref=53","year":"2020","unstructured":"Pegfilgrastim-gema compared to pegfilgrastim-roche for prevention of induced neutropenia in breast cancer patients. 2020"},{"key":"ref=54","year":"2020","unstructured":"SPI-2012 vs Pegfilgrastim in management of neutropenia in breast cancer patients with docetaxel and cyclophosphamide 2020. 2020"},{"key":"ref=55","year":"2020","unstructured":"Pegfilgrastim administered on the same day as chemotherapy in non-hodgkin\u2019s lymphoma. 2020"},{"key":"ref=56","year":"2020","unstructured":"Pegfilgrastim as support to advanced breast cancer patients receiving chemotherapy. 2020"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450123666220408101152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203279\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450123666220408101152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T14:30:24Z","timestamp":1660660224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203279\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450123666220408101152","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}